Groupama Asset Managment Has $130.09 Million Holdings in Boston Scientific Corporation $BSX

Groupama Asset Managment decreased its position in Boston Scientific Corporation (NYSE:BSX) by 5.5% during the 3rd quarter, Holdings Channel.com reports. The firm owned 1,332,481 shares of the medical equipment provider’s stock after selling 77,295 shares during the period. Groupama Asset Managment’s holdings in Boston Scientific were worth $130,090,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in BSX. Steph & Co. acquired a new position in Boston Scientific in the 3rd quarter valued at $25,000. Financial Consulate Inc. bought a new position in Boston Scientific during the 3rd quarter worth $25,000. Murphy & Mullick Capital Management Corp lifted its holdings in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 170 shares in the last quarter. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the second quarter valued at about $26,000. Finally, United Community Bank boosted its position in shares of Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 147 shares during the period. Institutional investors own 89.07% of the company’s stock.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific’s European urology portfolio expanded with sacral neuromodulation following the Axonics deal, supporting recurring revenue growth in a defensive medtech category. Sacral neuromodulation broadening Boston Scientific’s European urology portfolio
• Positive Sentiment: Analysts continue to rate BSX as a buy: UBS and Truist trimmed price targets (UBS $120→$105; Truist $95→$92) but retained buy ratings, signaling ongoing analyst conviction even after downward target adjustments. Benzinga analyst notes
• Neutral Sentiment: Coverage pieces position Boston Scientific as a defensive healthcare hedge versus cyclically sensitive sectors, which can attract flows in volatile markets but is not an immediate catalyst. The Highest-Rated Healthcare Stock to Buy Now
• Neutral Sentiment: Industry hires and competitor moves (e.g., Field Medical naming a new CEO with Medtronic experience) are notable for competitive dynamics but are not direct, immediate earnings catalysts for BSX. Field Medical appoints Mark Turco as CEO
• Negative Sentiment: Multiple law firms and plaintiff notices warn Boston Scientific investors of a securities‑class‑action covering purchases from July 23, 2025 to Feb 3, 2026, with a May 4, 2026 lead‑plaintiff deadline — this surge of legal filings/notices increases potential litigation risk and uncertainty. Rosen Law Firm investor alert
• Negative Sentiment: Specific allegations (highlighted by firms such as Levi & Korsinsky) claim executives misrepresented U.S. electrophysiology procedure volumes — if proven, these allegations could lead to meaningful financial and reputational impact. Levi & Korsinsky investor alert

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

BSX stock opened at $71.29 on Thursday. The company’s 50-day moving average price is $80.88 and its two-hundred day moving average price is $92.56. The firm has a market cap of $105.78 billion, a P/E ratio of 36.75, a P/E/G ratio of 1.00 and a beta of 0.69. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. Boston Scientific Corporation has a 12 month low of $67.56 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm’s quarterly revenue was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on BSX shares. UBS Group lowered their price target on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research report on Tuesday. Canaccord Genuity Group cut their price objective on shares of Boston Scientific from $112.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. TD Cowen lowered their target price on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. Royal Bank Of Canada dropped their price target on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Finally, The Goldman Sachs Group set a $99.00 price target on Boston Scientific in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Boston Scientific has a consensus rating of “Buy” and an average target price of $107.18.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.